Eli Lilly and Company
LLYPrice Effect (Buy)
Shares increased, but price decline reduced portfolio weight.
Shares +11.3% · Market value +9.8% · Weight -0.12%p
| Date | Action | ETF | Shares | Close | Est. total |
|---|---|---|---|---|---|
| 26.07.20 | BUY | ARKG | 2,730 | $1,146.90 | $3.1M |
| 26.07.08 | BUY | ARKG | 14,637 | $1,215.83 | $17.8M |
| 26.07.07 | BUY | ARKG | 6,354 | $1,235.56 | $7.9M |
| 26.06.25 | BUY | ARKG | 726 | $1,127.69 | $818.7K |
| 26.06.24 | BUY | ARKG | 7,293 | $1,117.26 | $8.1M |
| 26.06.18 | BUY | ARKG · ARKK | 8,487 | $1,098.57 | $9.3M |
| 26.06.17 | BUY | ARKG · ARKK | 41,138 | $1,112.00 | $45.7M |
| 26.03.03 | BUY | ARKG | 12,181 | $1,007.73 | $12.3M |
Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
Analyst Consensus
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Price Information
Trading Volume
Valuation
Financials
Profitability
Dividend
Technical
Eli Lilly and Company is a global pharmaceutical firm that discovers, develops, manufactures, and markets human pharmaceutical products. Its main offerings include treatments for cardiometabolic diseases like diabetes and obesity, oncology products for various cancers, and immunology and neuroscience medications. The company is a major player in the pharmaceutical industry, with a broad portfolio of innovative medicines.
AI-generated summary. Not investment advice.
Related ARK stocks
Explore companies with similar themes or neighboring ARK trading activity.